{"nctId":"NCT02209519","briefTitle":"Randomized Controlled Trial of Treatment of Male Partners of Women With BV","startDateStruct":{"date":"2015-02","type":"ACTUAL"},"conditions":["Recurrent Bacterial Vaginosis"],"count":214,"armGroups":[{"label":"Metronidazole","type":"EXPERIMENTAL","interventionNames":["Drug: Metronidazole (male partner)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placeob (male partner)"]}],"interventions":[{"name":"Metronidazole (male partner)","otherNames":[]},{"name":"Placeob (male partner)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: Female\n\n1. At least 18 years of age (19 years of age in Alabama due to State law)\n2. Sexual partner to a female who meets study eligibility\n3. Willingness to provide informed consent\n4. Willingness to abstain from sexual intercourse or use condoms {during the study}\n5. Willingness to abstain from alcohol for the first week of the study\n\nInclusion Criteria: Male\n\n1. At least 18 years of age (19 years of age in Alabama due to State law)\n2. Heterosexual with a regular partner\n3. History of 2 or more episodes of BV in the previous 12 months\n4. Symptoms of BV including vaginal discharge and/or odor\n5. Positive Amsel criteria for BV including vaginal pH \\>4.5, positive whiff test, presence of clue cells\n6. Willingness to provide informed consent\n7. Willingness to abstain from sexual intercourse or use condoms {during the study}\n8. Willingness to abstain from alcohol for the first week of the study\n\nExclusion criteria (both genders)\n\n1. Allergy to metronidazole\n2. Failure of the male partner to keep his appointment to be seen within 48 hours\n3. Pregnant or breast feeding (females)\n4. HIV or other chronic disease which in the opinion of the investigator would interfere with the ability to participate in this study\n5. Subject requires concurrent lithium, coumadin, dilantin, or antabuse\n6. Presence of trichomonas on wet prep of vaginal fluid (females)\n7. Women with a history of recurrent BV for \\>3 years or women who have failed previous treatment studies for BV","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Female Partners Whose Male Partners Received Metronidazole Versus Females Whose Male Partners Did Not Receive Metrodiazole With Recurrence of BV in the Female","description":"the female partners will be assessed for recurrence/persistence of BV. tRecurrence/persistence is measured by - Positive 3 - 4 Amsel criteria (vaginal pH \\> 4.7, clue cells, positive whiff test, homogenous discharge); Nugent score \\>3\n\nNo Recurrence/Persistence is measured by:\n\n\\- Presence of 0 -2 Amsel criteria; Nugent score 0-3.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recurrence of BV in Women Whose Partner Received Metronidazole Versus Females Whose Partners Did Not Receive Metronidazole","description":"time to recurrence measured in days","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Infections and infestations","gastrointestinal","nervous","respiratory","Injury"]}}}